4.7 Review

Neuronal hyperexcitability in Alzheimer's disease: what are the drivers behind this aberrant phenotype?

期刊

TRANSLATIONAL PSYCHIATRY
卷 12, 期 1, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41398-022-02024-7

关键词

-

资金

  1. International Postgraduate Tuition Award from the University of Wollongong
  2. National Health and Medical Research Council (NHMRC) of Australia Boosting Dementia Research Leadership Fellowship [APP1135720]
  3. Rebecca L. Cooper Medical Research Foundation [PG2020645, F2021971]
  4. NHMRC Early Career Fellowship [APP1105445]
  5. Brain Behavior Research Foundation (NARSAD Young Investigator Grant) [26486]

向作者/读者索取更多资源

Alzheimer's disease is a progressive neurodegenerative disorder with no cure. Identifying early changes in the disease course could provide new therapeutic targets. Hyperactivity is a characteristic in early stages of the disease, progressing to hypoactivity later. Neuronal excitability changes, including abnormal levels of intracellular Ca2+ and glutamate, pathological proteins, and genetic risk factors, play important roles. Hyperexcitability could be a predictive marker of cognitive dysfunction.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to loss of cognitive abilities and ultimately, death. With no cure available, limited treatments mostly focus on symptom management. Identifying early changes in the disease course may provide new therapeutic targets to halt or reverse disease progression. Clinical studies have shown that cortical and hippocampal hyperactivity are a feature shared by patients in the early stages of disease, progressing to hypoactivity during later stages of neurodegeneration. The exact mechanisms causing neuronal excitability changes are not fully characterized; however, animal and cell models have provided insights into some of the factors involved in this phenotype. In this review, we summarize the evidence for neuronal excitability changes over the course of AD onset and progression and the molecular mechanisms underpinning these differences. Specifically, we discuss contributors to aberrant neuronal excitability, including abnormal levels of intracellular Ca2+ and glutamate, pathological amyloid beta (A beta) and tau, genetic risk factors, including APOE, and impaired inhibitory interneuron and glial function. In light of recent research indicating hyperexcitability could be a predictive marker of cognitive dysfunction, we further argue that the hyperexcitability phenotype could be leveraged to improve the diagnosis and treatment of AD, and present potential targets for future AD treatment development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据